These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 34754290)

  • 1. Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: a meta-analysis of randomized clinical trials.
    Bazoukis G; Papadatos SS; Thomopoulos C; Tse G; Cheilidis S; Tsioufis K; Farmakis D
    J Geriatr Cardiol; 2021 Oct; 18(10):783-795. PubMed ID: 34754290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk.
    Bhatia K; Jain V; Gupta K; Bansal A; Fox A; Qamar A; Damman K; Vaduganathan M
    Eur J Heart Fail; 2021 Jun; 23(6):1002-1008. PubMed ID: 33609071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of different sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a network meta-analysis.
    Lan X; Zhu H; Cao Y; Hu Y; Fan X; Zhang K; Wu M
    Front Cardiovasc Med; 2024; 11():1379765. PubMed ID: 38845687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
    Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
    Am Heart J; 2021 Feb; 232():10-22. PubMed ID: 33214130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Zhao Z; Jin P; Zhang Y; Hu X; Tian C; Liu D
    Front Cardiovasc Med; 2022; 9():826684. PubMed ID: 35557542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ismayl M; Abbasi MA; Al-Abcha A; El-Am E; Lundgren S; Goldsweig AM; Anavekar NS
    Curr Probl Cardiol; 2023 May; 48(5):101597. PubMed ID: 36681210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of SGLT2 Inhibitors on Heart Failure Outcomes in Nondiabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Kommu S
    J Cardiovasc Pharmacol; 2024 Feb; 83(2):158-166. PubMed ID: 37989136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose cotransporter-2 inhibitors in heart failure: an updated meta-analysis.
    Cao Y; Li P; Li Y; Han Y
    ESC Heart Fail; 2022 Jun; 9(3):1942-1953. PubMed ID: 35338608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: A meta-analysis of randomized controlled trials.
    Li X; Zhang Q; Zhu L; Wang G; Ge P; Hu A; Sun X
    Int J Cardiol; 2021 Jun; 332():119-126. PubMed ID: 33838152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
    Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
    Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis.
    Täger T; Frankenstein L; Atar D; Agewall S; Frey N; Grundtvig M; Clark AL; Cleland JGF; Fröhlich H
    Clin Res Cardiol; 2022 Apr; 111(4):428-439. PubMed ID: 34498169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons from a pre-specified meta-analysis of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure: Time for new clinical recommendations.
    Kotit S
    Glob Cardiol Sci Pract; 2023 May; 2023(2):e202314. PubMed ID: 37351098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of SGLT2 inhibitors on cardiovascular events in patients with atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials.
    Zheng S; Lai Y; Jiang C; He L; Zhao Z; Li W; Tang R; Sang C; Long D; Du X; Ma C; Dong J
    Pacing Clin Electrophysiol; 2024 Jan; 47(1):58-65. PubMed ID: 38010824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis.
    Cardoso R; Graffunder FP; Ternes CMP; Fernandes A; Rocha AV; Fernandes G; Bhatt DL
    EClinicalMedicine; 2021 Jun; 36():100933. PubMed ID: 34308311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
    Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlström U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
    Eur J Heart Fail; 2021 Jun; 23(6):1012-1022. PubMed ID: 33599357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of SGLT2 inhibition on markers of reverse cardiac remodelling in heart failure: Systematic review and meta-analysis.
    Savage P; Watson C; Coburn J; Cox B; Shahmohammadi M; Grieve D; Dixon L
    ESC Heart Fail; 2024 Jul; ():. PubMed ID: 39056515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anemia and associated clinical outcomes in patients with heart failure due to reduced left ventricular systolic function.
    McCullough PA; Barnard D; Clare R; Ellis SJ; Fleg JL; Fonarow GC; Franklin BA; Kilpatrick RD; Kitzman DW; O'Connor CM; Piña IL; Thadani U; Thohan V; Whellan DJ;
    Clin Cardiol; 2013 Oct; 36(10):611-20. PubMed ID: 23929781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
    Musso G; Sircana A; Saba F; Cassader M; Gambino R
    PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.
    Kumar K; Kheiri B; Simpson TF; Osman M; Rahmouni H
    Am J Med; 2020 Nov; 133(11):e625-e630. PubMed ID: 32389659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of sodium-glucose cotransporter 2 inhibitors drugs among heart failure patients: a systematic review and meta-analysis.
    Soleimani H; Saeedian B; Pasebani Y; Babajani N; Pashapour Yeganeh A; Bahirai P; Navid H; Amin A; Samsky MD; Nanna MG; Hosseini K
    ESC Heart Fail; 2024 Apr; 11(2):637-648. PubMed ID: 38124239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.